Get started
NOVO-NORDISK ASNOVO-NORDISK ASNOVO-NORDISK AS

NOVO-NORDISK AS

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

NNO2 trade ideas

Novo Nordisk: 50% Drops Lead to Amazing GrowthFundamentals : Take a look at NVO in 1999-2000, 2003, 2008, 2016 and June 20024-2025. Every time it dropped about 50%, that lead to a huge rally for years! NVO has secured contracts with Medicaid for their diabetes and other drugs. It is not going anywhere. It has fallen 50%. We either hold or buy more. Technicals : uHd + extreme indicator +u3 volume last month +horizontal support + a-b-c + key fib pb Projection: 200 to 250 within two years, tentatively.
NYSE:NVOLong
by Rocketman
3/12/25 - $nvo - Hey now.. mr. mkt. i'll buy some3/12/25 :: VROCKSTAR :: NYSE:NVO Hey now.. mr. mkt. i'll buy some - i'm the first to tell you, i think pharma is rotton to the core - but let's play the game here, emotions r a PnL killa - sub 20x PE for 20-30% GROWTH? - 4%+ cash yields - EU's biggest co (and btw that's great orthogonal exposure to US tech) - healthcare "defensive", and you get growth here? - looks like i'll be ST call buying to get exposure higher on this sell off... but would also consider adding this to my 1-3% book that i'd like to rent over the coming 3-6 months while we chop sideways. thoughts? V
NYSE:NVOLong
by VROCKSTAR
4
Opening (IRA): NVO March 28th 76 Covered Call... for a 74.50 debit. Comments: Taking what amounts to a modest directional shot with a break even below the 52-week lows, selling the -75 delta call against shares to emulate the delta metrics of a 25 delta short put, but with the built-in defense of the short call. Metrics: Buying Power Effect/Break Even: 74.50 Max Profit: 1.50 ROC at Max: 2.01% 50% Max: .75 ROC at 50% Max: 1.00 Will generally look to take profit at 50% max and/or roll out the short call if my take profit isn't hit by expiry.
NYSE:NVOLong
by NaughtyPines
Finally a stock I like...this one is a real dealFinally, an investment idea! (after how much doom and gloom?) — Novo Nordisk. You will all be familiar with Ozempic, the Danish company’s flagship product and the reason so many celebrities, influencers, b listers and regular schmegular Americans are suddenly skinny. I ignored the stock for most of ‘23/24, because it was so expensive. I am still a value investor (for my sins) and I just didn’t see a lot of value there — it was priced in. Imagine my surprise as I was thinking about “megatrends” (vom) for the year ahead — AI, data, 'zempy. Novo stock has fallen 37.80% in the last six months. And you know what that means…that’s a real deal! Why is it a real deal? (Don’t you like booze stocks Eden?) Ozempic is not going away. At this point it is synonymous with weight loss as “Uber” is to ridesharing or Google is to search. Note this data per Barclays, from recently issued rx data in the US — Ozempic script issuance has grown +8.4%, while WeGovy slightly trails it at 7.4% — both owned by Novo. While Eli Lilly also makes a GLP, Novo is still the leader. Strong guidance from management on sales — +16% - 24% — roughly implies revenue of $48bn for ‘25 and $57bn for ‘26…that’s a compounder. America and much of the western world has an obesity problem. There is a clear incentive for governments to underwrite the drug because obesity has a clear social + fiscal cost on society — per UoA, the fiscal cost of obesity in NZ is at least $2bn¹. People have an incentive to use Ozempic, because they are vain. This is a nice hedge against the booze stocks I like so much. Benefit from both sides of the trade — buy booze at low teens multiples; buy Novo and benefit from lower drinking rates as there’s several studies that imply ‘Zempy reduces drinking. I don’t want Ozempic, because I like to live the good life. This does not mean the vast majority of people won’t use Ozempic. At the moment, one in eight Americans have used a GLP. That’s +334mn people. 40% of Americans are obsese. There’s a Lollapalooza effect happening here — a bunch of incentives — vain people, governments wanting less obese people, the various side health benefits of GLPs, etc. I like when a lot of incentives are aligned because you’re relying on psychology rather than projecting numbers on an excel spreadsheet. Novo has sold off recently due to a trial of its CagriSema drug missing expectations. Eyes on the prize, though — current GLPs, which still have plenty of market to saturate. Eli Lilly has traded up in recent times, while Novo has traded down. The two tend to trade in lockstep so the disconnect is an opportunity to buy the world’s leading GLP maker at a good price. Eli Lilly is the closest comp, but it trades at a 38x fwd multiple, while Novo trades at 20x — i.e. an almost 50% multiple discount (see chart). I like that too… Note analyst recs on chart also… This analysis is provided by Eden Bradfeld at BlackBull Research—sign up for their Substack to receive the latest market insights straight to your inbox.
NYSE:NVO
by BlackBull_Markets
1
Buy Opportunity for NVONovo Nordisk A/S – Financial Summary and Outlook (2024): Sales Growth: Up 23% in Danish kroner (DKK 204.7 billion) and 24% at constant exchange rates (CER). Operating Profit: Increased by 21% (DKK 91.6 billion). Net Profit: Rose 18% to DKK 72.8 billion. Product Highlights: Wegovy (Obesity): Sales surged 48% in Q3 (DKK 17.3 billion). Ozempic (Diabetes): Slight sales dip but remains a key contributor. Challenges: CagriSema Trial: Missed expected weight-loss targets, leading to stock decline. Outlook: Adjusted sales growth forecast: 23%-27%; operating profit: 21%-27% (CER). Focus remains on high-demand products (Wegovy, Ozempic) and R&D for future growth.
NYSE:NVOLong
by datavanza
$NVO more pain ahead! Headed down to $46-55 - NYSE:NVO was one of the hottest stocks of 2024 is now facing immense challenges by other healthcare companies in weight loss drug. - With weak results, it sets up for disappointment for 1-2 quarters. Quick turnaround in experiments isn't feasible and would need considerable time to show promising results. - It's better to put it on watchlist, attend earning call however it is likely that it might underperform FY 2025 or alteast first half of FY 2025.
NYSE:NVOShort
by bigbull037
7
Novo Nordisk | NVO | Long at $86.74The Good: NYSE:NVO expects its GLP-1 drugs Wegovy and Ozempic to soon come off the Food and Drug Administration's official shortage list. Just reported better-than-expected net profit in Q4 2024, amid soaring demand for its obesity drugs. Revenues for the Q4 2024 came in at $11.6 billion, up 30% compared to the same quarter in 2023. From a technical analysis perspective, hovering near my historical simple moving average which may lead to a near-term price increase due to positive earnings The Bad: Slower growth in 2025 (16%-24% for 2025 vs 18%-26% in 2024). Chart has been on a major run since 2020 and may be due for further correction. Personally, the positives outweigh the negatives given the obesity drug demand. Thus, at $86.74, NYSE:NVO is in a personal buy zone. Targets: $96.00 $105.00
NYSE:NVOLong
by WorthlessViews
Final Puke in Process - Wave 5We are approaching a strong trendline support level which begain back in 2017. The stock is heavily oversold, RSI is in a descending wedge pattern. We are also approaching the golden pocket Fibonacci retracement which can provide additional support. I expect a reaction at these levels and a breakout from the falling wedge pattern on the RSI. So far patience has been the best strategy, I do think this is the final Wave 5 of the correction and so this puke can continue a little further. It's hard to get the optimal entry on a falling knife, to play it safe you can await the wedge breakout with strong bullish volume. Not financial advise.
NYSE:NVOLong
by NoFOMO_
4
NVO: A Strong Buy Opportunity for 2025 **NVO: A Strong Buy Opportunity for 2025** 🚀📈 NVO is shaping up to be a compelling buy for this year. The setup is there, fundamentals remain strong, and the market conditions could favor a significant move. Keeping a close eye on key levels—this could be one of the best opportunities of 2025. Chart incoming on TradingView! 📊 #NVO #Investing #Trading #StockMarket Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump
NYSE:NVOLong
by Maximus20000
NVO presents an opportunityNVO has been getting absolutely slaughtered lately, I cannot help but be more bullish than ever on this. The stock falls deeper into the long-term demand zone. Stocks usually bottom on bad news, this is the market pricing the stock in as more and more bad news comes down the road. A final blow is given, and the market realizes the fundamentals do not match the price. This will happen for NVO. BBWP needs to cool off here, the stock needs to consolidate. Stochastic has reset.
NYSE:NVOLong
by Apollo_21mil
1/7/25 - $nvo - Probs a buy in low 80s... but...1/7/25 :: VROCKSTAR :: NYSE:NVO Probs a buy in low 80s... but... Friend who highlighted some good calls last year DM'd me (ty!) about this one. Figured i'd copy/paste my response in case anyone could add to this logic or is more knowledgeable on catalysts timing etc. 1/ i typically stay away from pharma (mainly bc i look at so many sectors and this is the singular one i've never covered professionally) 2/ the financials look great. growth, margins, cf generation - all "A" grade 3/ unclear how the NASDAQ:SAVA result will affect px performance in the coming days given diabetes seems to be a relevant part of the portfolio (but obviously this is a mega diversified name) so in short, it's defn a buy here, but given my conviction on maybe 5 other names that i can really size up, i've set an even greedier entry look closer to sub $80... not that i'd not own it here, but just i don't want to overcomplicate my book at the moment while i'm moving/ shaking aggressively on other stuff. 4/ also, what the banana hammock happened on dec 19 - unlocking that "event's bottom"/ implication looks like the key to determining how low this goes. it's already massively oversold, so if it wicks much further, it's simply a buy on mean reversion anyway - could probably pick up an easy 5+% under $80 without even trying (which is my lazy approach here). but i don't fault u if u own it - looks legit. 5/ options chain implying meager MT move keeps me wondering if this is dead money for the immediate term and i should only be a greedy buyer in the mid 70s. i think there's a way to generate yield here, but feels too risk adverse for my style (high octane) until i can gear it up at these lower levels with a better sense for mkt rippity-do-dah so - what do u think, anon? V
NYSE:NVOLong
by VROCKSTAR
NVO LongNovo Nordisk, a global leader in diabetes and obesity treatments, has traditionally maintained a solid financial standing with strong revenue growth, impressive profitability, and a robust pipeline of new treatments. However, the company has recently faced a significant dip in its stock price, largely due to market concerns related to its obesity treatment segment. While these concerns may reflect short-term volatility or market uncertainty, it’s important to recognize that the company's underlying fundamentals remain strong. When evaluating the company through the lens of intrinsic value indicators—such as discounted cash flow analysis, price-to-earnings ratios, and projected growth rates—Novo Nordisk appears to be trading at a favorable price relative to its long-term growth potential. This suggests that, despite the recent drop in stock price, the company’s shares may be undervalued, offering a potentially attractive entry point for investors who are willing to take a long-term view. In the long run, the obesity treatment market is expected to grow, and Novo Nordisk’s leadership in this space, along with its diversified portfolio and innovation-driven strategy, could well position it to benefit from future market developments. Therefore, the current stock price may present a buying opportunity for those who believe in the company’s continued strength and market leadership. #DYOR
NYSE:NVOLong
by zdmre
1